innoscripta SE has reported a robust financial performance for the first half of 2026, with revenue surging 43% year-on-year to EUR 63.1 million. The company's adjusted EBIT rose 49% to EUR 36.4 million, reflecting an adjusted EBIT margin of 57.7%. This growth underscores the increasing demand for its R&D tax allowance services and the scalability of its Clusterix platform.
The German R&D tax allowance (Forschungszulage) continues to be a key growth driver, attracting more than 2,900 customers during the period. The company has further strengthened Clusterix as its central infrastructure for project structuring, data management, and application submissions. This enhancement enables automated data validation, higher data quality, and faster, more standardized processes, while establishing consistent workflows across different markets. This technological foundation is critical for the company's international scaling efforts.
International expansion has progressed as planned, with successful market entries into France, the UK, and the US. In France, innoscripta opened its first location near Toulouse and has already secured customers. The UK market entry began with a Manchester office as of July 1, 2026, and the company is now active in the US, serving its first clients in this high-growth market. Clusterix's flexibility in adapting to different regulatory requirements has enabled efficient entry into new markets, a key competitive advantage.
The Management Board confirms its guidance for the full year 2026, expecting group revenue of at least EUR 140 million and EBIT of at least EUR 80 million, assuming consistent timing of customer application submissions and approvals. Detailed financial figures are available in the Half-Year Report on the company's website in the Investors section.
innoscripta will host a virtual earnings call today at 3:00 p.m. CEST to discuss the H1 2026 results, with dial-in details available on the company's website under Investor Events.
This strong first-half performance highlights the company's successful execution of its growth strategy, driven by technological innovation and strategic market expansion. As innoscripta continues to scale internationally, its robust infrastructure and proven business model position it well for sustained growth in the R&D tax allowance market.
